<SEC-DOCUMENT>0001654954-18-001025.txt : 20180202
<SEC-HEADER>0001654954-18-001025.hdr.sgml : 20180202
<ACCEPTANCE-DATETIME>20180202090043
ACCESSION NUMBER:		0001654954-18-001025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180202
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20180202
DATE AS OF CHANGE:		20180202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TG THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32639
		FILM NUMBER:		18568853

	BUSINESS ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		(212) 554-4484

	MAIL ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MANHATTAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20030310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tgtx8-kreactrimspr.htm
<DESCRIPTION>V020218_8K
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">UNITED
STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
WASHINGTON, D.C.</font> <font style="font-size: 13px">20549</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">_____________</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">FORM
8-K</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">_____________</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CURRENT
REPORT</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Pursuant
to Section 13 or 15(d) of the</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Securities
Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date of
report (Date of earliest event reported): <font style="font-weight: bold">February 2, 2018</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG
Therapeutics, Inc.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
Name of Registrant as Specified in Charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 32%">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Delaware</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
or Other Jurisdiction</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">of
Incorporation)</font></div>
</td>
<td style="vertical-align: top; width: 30%">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">001-32639</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Commission File
Number)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 38%">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">36-3898269</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer Identification No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">2
Gansevoort Street, 9<font style="font-size: 70%; vertical-align: top">th</font> Floor</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">New
York, New York 10014</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Address of
Principal Executive Offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(212)
554-4484</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Registrant's
telephone number, including area code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><font>&#x2610;</font></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Written
communications pursuant to Rule 425 under the Securities
Act.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><font>&#x2610;</font></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Soliciting material
pursuant to Rule 14a-12 under the Exchange Act.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><font>&#x2610;</font></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><font>&#x2610;</font></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&#xA7;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#xA7;240.12b-2). Emerging growth company <font>&#x2610;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <font>&#x2610;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 8.01. Other Events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 14px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
February 2, 2018, TG Therapeutics, Inc. (the &#x201C;Company&#x201D;)
issued a press release announcing results from the Phase 2
multicenter trial of ublituximab (TG-1101), the Company&#x2019;s
novel glycoengineered anti-CD20 monoclonal antibody, in relapsing
forms of Multiple Sclerosis (RMS) presented during the
3<font style="font-size: 70%; vertical-align: top">rd</font> Annual
Americas Committee for Treatment and Research in Multiple Sclerosis
(ACTRIMS) Forum 2018 in San Diego, CA. A copy of the press release
is being filed as Exhibits 99.1and incorporated in this Item by
reference.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 96px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
9.01&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Financial
Statements And Exhibits.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">(d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Exhibits.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px"><a href="v020218_8k.htm">99.1</a><font style="color: #000000">&#xA0;</font>&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Press Release,
dated February 2, 2018.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">- 2
-</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: -48px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 336px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">TG
Therapeutics, Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 14px; text-indent: 336px">
<font style="font-family: Times New Roman; font-size: 13px">(Registrant)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
February 2, 2018</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 336px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:_<font style="text-decoration: underline">/s/ Sean A.
Power</font>__________</font></div>
<div style="text-align: left; margin-left: 360px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sean A.
Power</font></div>
<div style="text-align: left; margin-left: 360px; margin-right: 14px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Financial Officer</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div id="pn" style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">- 3
-</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v020218_8k.htm
<DESCRIPTION>V020218_EX991
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
TG Therapeutics, Inc. Announces Updated Results from the Ongoing
Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple
Sclerosis at the Third Annual ACTRIMS Forum 2018</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
100% reduction of T1 Gd-enhancing lesions at week 24
(n=38)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
99% median B-cell depletion was observed at week 4 and maintained
at week 24 (n=40)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
TG-1101 was well tolerated across all patients including those
receiving 1 hour infusions at the Phase 3 dose</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">New
York, NY, (<font style="font-weight: bold">February 2, 2018</font>)
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced results from
the Phase 2 multicenter trial of ublituximab (TG-1101), the
Company&#x2019;s novel glycoengineered anti-CD20 monoclonal
antibody, in relapsing forms of Multiple Sclerosis (RMS). The data
was presented last night during Poster Session 1, from 6:00 PM
&#x2013; 8:00 PM PT, at the 3<font style="font-size: 70%; vertical-align: top">rd</font> Annual Americas
Committee for Treatment and Research in Multiple Sclerosis
(ACTRIMS) Forum 2018, in San Diego, California.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Michael S. Weiss, the Company&#x2019;s Executive Chairman and Chief
Executive Officer, stated, &#x201C;We are very pleased with the
updated Phase 2 data presented last night which now includes 5
cohorts, totaling 40 patients. It&#x2019;s exciting to see that with
more patients through 6 months of treatment, the data remain
consistent with the earlier results presented at the 2017
ECTRIMS-ACTRIMS meeting. The data continue to demonstrate the
positive effects of ublituximab with sustained B-cell depletion
through Week 24, complete elimination of T1 Gd-enhancing lesions
and 97.5% of subjects without a relapse at Week 24. Importantly,
the 1 hour infusion appears to be well tolerated and could
represent a more convenient alternative to the currently marketed
anti-CD20 monoclonal antibody.&#x201D; Mr. Weiss continued,
&#x201C;We look forward to presenting additional updated Phase 2
data, including data from all 48 patients enrolled in the Phase 2
study through 52 weeks, while we continue to enroll into our global
Phase 3 ULTIMATE trials.&#x201D;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
This Phase 2 trial is a 52-week randomized, placebo controlled,
multi-center study evaluating the safety and efficacy of
ublituximab at accelerated infusion times as fast as one hour.
Today&#x2019;s poster includes 6 month data from the first 40
patients (of 48 enrolled, 8 too early to evaluate) with RMS that
were treated with ublituximab across five dosing
cohorts.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
<font style="text-decoration: underline; color: #000000">Poster
Presentation Title:</font><font style="color: #000000">&#xA0;</font>6 Month Results of a Phase 2a
Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20
Monoclonal Antibody, in Relapsing Multiple Sclerosis</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Poster Highlights:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">99% median B-cell
depletion was observed at week 4 and maintained at week 24 (6
months) (n=40)</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Ublituximab
completely eliminated all (100%) of T1 Gd-enhancing lesions at week
24 (n=38) (p=0.0005)</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">97.5% of subjects
(39/40) were relapse free at week 24</font></div>
</div>
</div>
<div style="margin-left: 72px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">o</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">One confirmed
relapse was reported, in Cohort 1. The patient was initially
randomized to the placebo arm. The relapse occurred 12 days after
the patients&#x2019; first infusion of 150mg of TG-1101. The patient
remains on study and has received the second and third infusions of
TG-1101 and to date has remained relapse free.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Mean EDSS
improvement from baseline of 0.3 with 78% of subjects showing
improved or stable EDSS</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Ublituximab was
well tolerated across all patients including those receiving rapid
infusions, as low as a one hour for the 450mg Phase 3
dose</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
These data presentations support the international Phase 3 ULTIMATE
program evaluating ublituximab for the treatment of relapsing form
of Multiple Sclerosis (RMS). The Phase 3 trials, entitled ULTIMATE
I and ULTIMATE II, are being conducted under Special Protocol
Assessment (SPA) agreement with the U.S. Food and Drug
Administration (FDA) and are being led by Lawrence Steinman, MD, of
Stanford University. The ULTIMATE trials are currently enrolling
and complete enrollment is expected in the first quarter of
2019.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
POSTER</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">A copy
of the above poster can be found on the Publications page, located
within the Pipeline section, of the Company&#x2019;s website at
<font style="text-decoration: underline; color: #0000FF">www.tgtxinc.com/publications.cfm</font>.</font></div>
&#xA0; <font style="font-family: Times\ New\ Roman; font-size: 13px;"><br>
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
ABOUT TG THERAPEUTICS, INC.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><a name="_Hlk502743796"><!--anchor--></a>TG Therapeutics&#xA0;is a
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. Currently, the company is developing two
therapies targeting hematological malignancies and autoimmune
diseases. Ublituximab (TG-1101) is a novel, glycoengineered
monoclonal antibody that targets a specific and unique epitope on
the CD20 antigen found on mature B-lymphocytes.&#xA0;TG
Therapeutics&#xA0;is also developing umbralisib (TGR-1202), an
orally available PI3K delta inhibitor. The delta isoform of PI3K is
strongly expressed in cells of hematopoietic origin and is believed
to be important in the proliferation and survival of
B&#x2010;lymphocytes. Both ublituximab and umbralisib, or the
combination of which is referred to as "U2", are in Phase 3
clinical development for patients with hematologic malignancies,
with ublituximab also in Phase 3 clinical development for Multiple
Sclerosis. Additionally, the Company has recently brought its
anti-PD-L1 monoclonal antibody into Phase 1 development and aims to
bring additional pipeline assets into the clinic in the
future.&#xA0; TG Therapeutics&#xA0;is headquartered in&#xA0;New
York City.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Cautionary Statement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Statements
included in this press release, particularly those with respect to
anticipating the benefit of the early data seen in the Phase 2 MS
trial and anticipating the timing of our MS Phase 3 program may be
forward-looking statements that involve a number of risks and
uncertainties.&#xA0; For those statements, we claim the protection
of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.&#xA0; Among the
factors that could cause our actual results to differ materially
are the following: our ability to successfully and cost-effectively
complete the MS Phase 2 and Phase 3 trials; the risk that early
clinical results that supported our decision to move forward will
not be reproduced in additional patients in expansion cohorts or in
the MS Phase 3 program;the risk that data included in any poster
presentation will not be reproduced in subsequent data
presentations;the risk that the clinical results from the MS Phase
3 program, will not be positive and/or will not support regulatory
approval of ublituximab for MS; the risk that ublituximab will not
have a differentiated profile from the other drugs in the class and
that early signs of best-in-class attributes will not be supported
by future results; the risk that trials will take longer to enroll
than expected; our ability to achieve the milestones we project
over the next year; our ability to manage our cash in line with our
projections, and other risk factors identified from time to time in
our reports filed with the&#xA0;Securities and Exchange Commission.
&#xA0;Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not
undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available
at&#xA0;<font style="text-decoration: underline; color: #0000FF">www.tgtherapeutics.com</font>.
The information found on our website is not incorporated by
reference into this press release and is included for reference
purposes only.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CONTACT:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Jenna
Bosco</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Vice President,
Investor Relations</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">TG Therapeutics,
Inc.</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Telephone:
212.554.4351</font></div>
</div>
</div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-size: 13px; font-family: Times New Roman">Email:
ir@tgtxinc.com</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 2px; background-color: rgb(0, 0, 0);">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
